LENZ Therapeutics (LENZ) Competitors $32.63 +2.35 (+7.76%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LENZ vs. DNLI, TWST, VCEL, SWTX, KYMR, IOVA, BEAM, RXRX, APGE, and IBRXShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vericel (VCEL), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry. LENZ Therapeutics vs. Denali Therapeutics Twist Bioscience Vericel SpringWorks Therapeutics Kymera Therapeutics Iovance Biotherapeutics Beam Therapeutics Recursion Pharmaceuticals Apogee Therapeutics ImmunityBio Denali Therapeutics (NASDAQ:DNLI) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership. Do analysts recommend DNLI or LENZ? Denali Therapeutics currently has a consensus target price of $40.40, suggesting a potential upside of 88.34%. LENZ Therapeutics has a consensus target price of $35.40, suggesting a potential upside of 8.49%. Given Denali Therapeutics' higher possible upside, research analysts plainly believe Denali Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more risk & volatility, DNLI or LENZ? Denali Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Is DNLI or LENZ more profitable? Denali Therapeutics' return on equity of -32.94% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% LENZ Therapeutics N/A -58.48%-55.50% Does the MarketBeat Community prefer DNLI or LENZ? Denali Therapeutics received 441 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 67.82% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes45167.82% Underperform Votes21432.18% LENZ TherapeuticsOutperform Votes10100.00% Underperform VotesNo Votes Which has better valuation and earnings, DNLI or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M9.34-$145.22M-$2.76-7.77LENZ TherapeuticsN/AN/A-$124.65MN/AN/A Do insiders and institutionals hold more shares of DNLI or LENZ? 92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 7.9% of Denali Therapeutics shares are held by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer DNLI or LENZ? In the previous week, Denali Therapeutics had 7 more articles in the media than LENZ Therapeutics. MarketBeat recorded 13 mentions for Denali Therapeutics and 6 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.08 beat Denali Therapeutics' score of 1.03 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDenali Therapeutics beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Brownstone ResearchMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$897.36M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E RatioN/A46.7391.3417.19Price / SalesN/A411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / Book1.483.894.794.78Net Income-$124.65M-$42.21M$120.07M$225.60M7 Day Performance5.36%-2.14%-1.90%-1.24%1 Month Performance-4.81%4.21%11.43%3.06%1 Year PerformanceN/A18.40%30.59%16.50% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics0.49 of 5 stars$32.63+7.8%$35.40+8.5%N/A$897.36MN/A0.00N/ANews CoveragePositive NewsHigh Trading VolumeDNLIDenali Therapeutics4.4235 of 5 stars$23.69+3.1%$40.40+70.5%+1.3%$3.41B$330.53M-8.49364Positive NewsTWSTTwist Bioscience2.5561 of 5 stars$48.87+2.9%$51.90+6.2%+36.7%$2.90B$312.97M-13.19990VCELVericel1.4381 of 5 stars$57.54+0.1%$59.71+3.8%+66.0%$2.84B$226.84M957.83300Analyst ForecastSWTXSpringWorks Therapeutics2.0068 of 5 stars$38.16-0.4%$69.50+82.1%+11.3%$2.84B$5.45M-9.87305KYMRKymera Therapeutics2.27 of 5 stars$43.54+3.3%$53.88+23.8%+66.0%$2.82B$87.56M-18.00170IOVAIovance Biotherapeutics4.0084 of 5 stars$7.89+0.8%$22.33+183.1%+2.8%$2.40B$1.19M-5.25500BEAMBeam Therapeutics3.426 of 5 stars$28.74+2.9%$47.67+65.9%+5.0%$2.38B$349.64M-15.87461RXRXRecursion Pharmaceuticals2.4142 of 5 stars$7.51+8.1%$9.25+23.2%-36.3%$2.15B$44.58M-4.85400News CoverageHigh Trading VolumeAPGEApogee Therapeutics2.5994 of 5 stars$46.76+5.1%$83.88+79.4%+92.5%$2.11BN/A-18.3991IBRXImmunityBio2.1284 of 5 stars$3.01+4.9%$17.38+477.2%-42.2%$2.10B$7.33M-3.36590Analyst Forecast Related Companies and Tools Related Companies DNLI Competitors TWST Competitors VCEL Competitors SWTX Competitors KYMR Competitors IOVA Competitors BEAM Competitors RXRX Competitors APGE Competitors IBRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LENZ) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
